Group items matching

in title, tags, annotations or url

The FY18 KCRP Idea Development Award is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the KCRP vision of eliminating kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. Personnel on the proposed team should have a strong background in kidney cancer research. The anticipated direct costs budgeted for the entire period of performance for an FY18 KCRP Idea Development Award will not exceed $400,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

This Funding Opportunity Announcement (FOA) invites applications to establish research teams of the Small-Cell Lung Cancer (SCLC) Consortium to conduct research whose overall goals are: 1) to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy. This FOA focuses on two of the five research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Small Cell Lung Cancer (SCLC). Additional priorities of the Framework are stated in this FOA, as studies are expected to use or develop state-of-the-art research tools and omic profiles to identify therapeutic strategies that are relevant to human SCLC disease progression and resistance. The research supported by this FOA will be performed by individual research teams who are expected to collaborate with one another and with a central SCLC Coordinating Center. A third component of the SCLC Consortium focuses on prevention and early detection of SCLC.

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career Development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career Development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.

Applications to the Fiscal Year 2017 (FY17) Lung Cancer Research Program (LCRP) are being solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 2358 (10 USC 2358). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The execution management agent for this Program Announcement is the Congressionally Directed Medical Research Programs (CDMRP). The LCRP was initiated in FY09 to promote innovative and competitive research focused on the Development of integrated disciplines to identify, treat, and manage early curable lung cancer (excluding mesothelioma).

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are non-responsive to this solicitation and will not be reviewed.

The purpose of the International Research Scientist Development Award (IRSDA) is to provide support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty (applicants must be at least two years beyond conferral of doctoral degree) for an intensive, mentored research career Development experience in a low- or middle-income country (LMIC), as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups, including "low-income," "lower-middle-income," and "upper-middle-income" countries) leading to an independently-funded research career focused on global health. This Funding Opportunity Announcement (FOA) invites applications from postdoctoral research scientists and junior faculty from any health-related discipline who propose career Development activities and a research project that is relevant to the health priorities of the LMIC under the mentorship of LMIC and U.S. mentors.        

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon Development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model Development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon Development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model Development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. FOA Emphasis. This FOA utilizes the R33 mechanism and is suitable for projects, which have overcome major feasibility gaps for the technology or methodology as demonstrated with supportive preliminary data but still require further development and rigorous validation to encourage adoption by the research community. Proposed projects should offer the potential to produce a molecular or cellular analysis capability with a major impact in a broad area of cancer-relevant research.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions with expertise and innovative strategies for developing research and mentoring opportunities for undergraduate students from backgrounds underrepresented in biomedical research to submit applications for 6 month planning grants for the NIH Building Infrastructure Leading to Diversity (BUILD) initiative. The BUILD initiative aims to increase the diversity of the NIH-funded workforce by supporting collaborative programs that include novel approaches for enhancing undergraduate education, training, and mentorship, as well as infrastructure support and faculty development to facilitate those approaches. BUILD planning grants are intended to help institutions develop the necessary partnerships and infrastructure needed to be competitive for the BUILD initiative.

The Melanoma Research Foundation is accepting applications from emerging and established scientific investigators for research projects that explore new avenues in melanoma biology, prevention and treatments, with the goal of finding a cure. The foundation makes grants in four areas: Career Development Awards, Established Investigator Awards, Career Investigator CURE OM Awards, and Established Investigator CURE OM Awards. Career Development Awards provide funding of up to $50,000 a year for two years to junior investigators who are beginning a research career emphasizing melanoma-related projects and have not yet secured strong federal funding for their research. Established Investigator Awards provide funding of up to $100,000 a year for two years to established melanoma researchers or senior researchers working in closely related fields who wish to move into melanoma research. Career Development CURE OM Awards provide funding of up to $50,000 a year for two years to junior investigators in the ocular/uveal melanoma field. Established Investigator CURE OM Awards provides funding of up to $100,000 a year for two years to established ocular/uveal melanoma researchers, or senior researchers.

Advance your career by visiting another institute: American Cancer Society international fellowships for beginning investigators (ACSBI). The ACSBI fellowship emphasizes the transfer of knowledge from the host institute to others at the home institute. It offers the fellow the opportunity to be mentored by experts in the chosen field, receive hands on experience in clinical, behavioural or basic research, intellectual stimulation, research guidance, narrative transfer and many other opportunities to evolve scientifically and academically. The goals include not only developing future leaders in cancer research in low/middle income countries, but also facilitating a global effort in cancer prevention and control. This will be done by developing the necessary intellectual infrastructure in home countries (since ACSBI fellows must return to their home institute), encouraging collaborative interactions to facilitate interdisciplinary basic and applied cancer research, and establishing a network of researchers and translational scientists for rapid dissemination of new knowledge and technology in developing and sharing of best practices.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to): * Genetics (Molecular, Pharmaco-, Population, Medical) * Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative) * Systems (Biology and Pharmacology) * Pathways and networks * Integrative biology * Modeling and simulation * Target Identification and Validation * Biomarker Discovery and Validation * Vaccine development * Molecular Epidimiology * Imaging * Disease Modeling

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

This Funding Opportunity Announcement (FOA) is a new initiative to support the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs).  Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost devices or assays that are clinically comparable to currently used technologies for imaging, in vitro detection/diagnosis, or treatment of cancers in humans living in LMICs. Funds will be made available through the UH2/UH3 phased innovation cooperative agreement award mechanism.  Applicants should have a working assay or prototype (not necessarily already capable of cancer applications).  The initial 2-year (or shorter) UH2 exploratory phase will be a feasibility study to demonstrate technical functionality and clinical potential for use in LMIC settings by meeting specific performance milestones.  UH2 projects that have met their milestones will be administratively considered by NCI and prioritized for transition to the UH3 validation phase.  UH3 awards will support improvements and validations of the technologies in the LMIC settings.  The project period for the UH3 phase is up to 3 years.  Projects proposed in response to this FOA will require multidisciplinary efforts to succeed and therefore all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development.  Investigators responding to this FOA must address both UH2 and UH3 phases.

Call for Applications: Pancreatic Cancer Action Network - American Association for Cancer Research Career Development Award Supports a junior faculty member in developing or strengthening their pancreatic cancer research

This Funding Opportunity Announcement (FOA) is a part of the Pediatric Preclinical Testing Consortium (PPTC) initiative. The PPTC will consist of in vivo and in vitro testing Research Programs (both supported under companion RFA-CA-14-018) and the PPTC Coordinating Center (supported under this FOA). The PPTC is designed to address key challenges associated with the development of new therapies for children with cancer by developing reliable preclinical testing data for pediatric drug candidates that can be used to inform new agent prioritization decisions. Effective prioritization is critical because of the large universe of drugs being developed for adult cancers, a number so large that no more than a small number can be studied in pediatric clinical trials. Identifying through preclinical testing those investigational agents most likely to have clinical activity for selected childhood cancers accelerates the pace at which treatments that are more effective than the current ones can be identified and incorporated into standard practice for children with cancer. The PPTC Research Programs, responsible for conducting the in vivo and in vitro testing of selected agents, will be focused on specific tumor types that are particularly relevant to pediatric oncology. The PPTC Coordinating Center, which is subject of this FOA, will be responsible for integrating the activities of the individual PPTC Research Programs to create a functional consortium for pediatric preclinical testing. Specifically, the PPTP-Coordinating Center will provide administrative coordination and infrastructure, data management and statistical support, as well as Consortium scientific coordination.

A cancer survivor is a person diagnosed with cancer, from the time of diagnosis throughout the person’s lifespan. As of 2008, nearly 12 million cancer survivors were living in the United States; this number is expected to increase to 18 million in 2020. Cancer survivors have long-term adverse physical and psychosocial effects from their diagnosis and treatment, and have a greater risk for additional cancer diagnoses compared with persons without a cancer history. Cancer survivors commonly report negative behavioral, medical, and health care access issues that may contribute to poor long-term medical and psychosocial outcomes. An analysis of over 45,000 U.S. cancer survivors showed that: 1) 15% of cancer survivors continue to use tobacco; 2) 20-25% do not receive recommended cancer screenings; 3) 31% do not engage in any leisure time physical activity; 4) 40 to 50% do not receive flu or pneumonia vaccines; 5) 60% do not have a summary of their cancer treatment; and 6) 25% do not have any instructions (written or oral) for their treatment or follow-up care . CDC’s National Comprehensive Cancer Control Program (NCCCP) supports collaborative cancer control and prevention efforts in all states, the District of Columbia, tribal organizations, territories, and Pacific Island jurisdictions to address the cancer burden in their jurisdictions. In 2010, NCCCP developed six priorities areas of focus for the greatest public health impact; one of the six priorities is to address the public health needs of cancer survivors. The purpose of this FOA is to implement a broad set of evidence-based survivorship strategies in a subset of NCCCP grantees that will have the short-term results of increasing knowledge of cancer survivor needs, increasing survivor knowledge of treatment and follow-up care, and increasing provider knowledge of guidelines pertaining to treatment of cancer. Intermediate outcomes include the development of best practices in survivorship among NCCCP gra